News

August 2024

We published  :

  • The new review: "Immune checkpoint inhibitors + platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer" and 
  • our first protocol on prognosis entitled: "Overall prognosis of index lung cancer recurrence or of second primary lung cancer in people with non-small cell lung cancer operated with complete resection".

 

March 2024

The group has 2 new publications: :

  • A review: "Therapeutic vaccines for advanced non-small cell lung cancer" and
  • A protocol: "First-line systemic treatment for people with extensive stage small cell lung cancer"

 

September 2023

Members of the Lung Cancer Group attended the colloquium which took place in London. During this event, we said goodbye to our colleague and friend Fergus Macbeth who stepped down from his co-ed role. We wish him all the best for his new life. 

https://events.cochrane.org/colloquium-2023/about-colloquium

 

 

July 2023

Publication of a review entitled :
 

- Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

 

 

August 2022

We published the review :
 

- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality 

 

April 2022

We published 2 new protocols :
 

- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation,

- Stereotactic body radiation therapy versus more fractionated radical radiotherapy for adults with stage I/II non-small cell lung cancer: a systematic review and network meta-analysis

 

 

December 2021

we published a new review:
 

- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer,

the review: Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent was updated and we published a new protocol:

- Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide versus platinum-etoposide alone for first-line treatment of extensive small cell lung cancer

May 2021
 

We published a new protocol entitled :
 

- Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

 

March 2021
 

2 new publications from the Lung Cancer Group are available in the Cochrane Library:

- The update of the review : First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer which includes 3 new studies
 

- a new protocol entitled Prophylactic cranial irradiation for extensive-stage small cell lung cancer

 

December 2020/ January  2021
 

We published our 1st 'living review' entitled : 
- Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

and an new protocol on screening entitled:
- Low-dose computed tomography (LDCT) screening for lung cancer-related mortality

 

 

September 2020

We published two new protocols:

- Prophylactic cranial irradiation for patients with limited-stage small cell lung cancer, and
- Limited resections versus lobectomy for stage I non-small cell lung cancer.

 

 

January / February 2020

We published the updates of the reviews:

- Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
- Drugs for preventing lung cancer in healthy people.

 

 

 

 

October 2019

We published three new protocols:

- Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status,

- Altered fractionation of thoracic radiation therapy for localised small cell lung cancer, and

- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.

 

June 2019

We published a new protocol 'Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol' and 2 reviews were updated: 'Interventions for smoking cessation in people diagnosed with lung cancer' and 'Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer'
 

 

 

May 2019

We all met for a working session in Paris on 7th May 
 

 

February 2019

We published a new review: Exercise training for advanced lung cancer and a new protocol: Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. This will be a living review (a systematic review which is continually updated, incorporating relevant new evidence as it becomes available). 
 

More information on that new format can be found here: https://community.cochrane.org/review-production/production-resources/living-systematic-reviews

 

We also published an update of the review : Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients

 

December 2018

We published a new protocol: Gabapentinoids for chronic post-thoracotomy pain after lung surgery in adults

 

 

 

 

September 2018

Corynne Marchal, Fergus Macbeth and Francois Calais attended the 25th Cochrane Colloquium in Edinburgh

                    

 

May 2018

We published two new protocols: Third-line systemic chemotherapy for small cell lung cancer and Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lun cancer which is a generic protocol that will lead to 2 reviews : 
 

- PD1 / PD-L1 inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer

- CTLA4 inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer

 

April 2018

 

We published a new protocol: Chemo-radiotherapy versus surgery-based treatment for Stage IIIA non-small cell lung cancer: a systematic review and network meta-analysis

 

 

January 2018

We published 2 news reviews: Gefitinib for advanced non-small cell lung cancer' and 'Radical multimodality therapy for malignant pleural mesothelioma' and a protocol : 'Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non–small-cell lung cancer wild-type or unknown status for EGFR'

 

 

December 2017

 

This month we have published a new review entitled: 'Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent'

September 2017

 

Fergus Macbeth attended the Global Evidence Summit in Cape Town (South Africa) from 13th to 16th September (www.globalevidencesummit.org/about-summit) . It was the first time that Cochrane, The Campbell Collaboration, Guidelines-International Network, International Society for Evidence-based Health Care, and Joanna Briggs Institute have joined forces to create the premiere event in evidence-based policy. 

 

June 2017

 

We have published a new review: 'Preoperative exercise training for patients with non-small cell lung cancer' and one protocol: 'Exercise training for advanced lung cancer'

 

April 2017

 

We published a new review: 'surgery for limited-stage small-cell lung cancer' and one protocol: 'Video-assisted thoracoscopic lobectomy versus open thoracotomy conventional lobectomy for stage I non-small cell lung cancer'

 

Fergus Macbeth attended the Cochrane mid-year meeting in Geneva (Switzerland) in early April where he represented our group to all of the meetings.

 

March 2017

 

 

 

We published a new protocol : Radical multimodality therapy for malignant pleural mesothelioma

January 2017

 

 

 

We published a new protocol : Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma

 

 

October 2016

Corynne Marchal and Fergus Macbeth attended the 24th cochrane Colloquium in Seoul (https://colloquium.cochrane.org/)

colloquium               workshop

 

September 2016

 

We published the update of the review : Postoperative radiotherapy for non-small cell lung cancer

 

May 2016

We published a new review: First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

April 2016
 

We registrered 1 new title:

  •  Combined multimodal radical therapy for malignant pleural mesothelioma

February 2016
 

We registrered 2 new titles:

  •  Early stage non-small cell lung cancer: Radical mediastinal lymph node dissection versus mediastinal nodal sampling
  • and a DTA title : Mini-invasive procedures for the staging of non-small cell lung cancer
     

January 2016
 

We  registrered 2 new titles:
 

  •  Chemotherapy versus chemotherapy in combinaison with a targeted therapy as second-line treatment for advanced non-small cell lung cancer wild-type or unknown status for epidermial growth factor receptor: a systematic review and meta-analysis
  • and Vaccines for advanced non-small cell lung cancer

 

December 2015

We published

  •  a new review: Interventions for smoking cessation in people diagnosed with lung cancer
  • and a new protocol: Preoperative exercise training for patients with non-small cell lung  cancer

 

October 2015

  • Corynne Marchal and Francois Calais attended the 23rd cochrane Colloquium in Vienna (https://colloquium.cochrane.org/)

    AGM

    We published
  • a new review : chemotherapy for advanced non-small cell lung cancer in the elderly population
  • and a new protocol: surgery localised small cell lung cancer

 

September 2015

  • We published a new review: non-invasive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
We were present at the ERS International Congress 2015 in Amsterdam (http://erscongress.org/home-ams2015)
Amsterdam
and ran a symposium on "How to perform and interpret systematic reviews and meta-analyses"

 
Chairs
 
- Introduction to writing a systematic review: the example of the Cochrane Collaboration F. Macbeth (Bristol, United Kingdom) 
 
- Defining a review question and writing a protocol J. Trappenburg (Utrecht, Netherlands)
- (Non-)sense to interpret meta-analyses with heterogeneous interventions: the example of non-pharmacological interventions M. Puhan (Zurich, Switzerland) 
- From meta-analyses to network meta-analyses: the Holy Grail for assessing interventions? L. Trinquart (Paris, France) 

 
approximately 500 people attended the symposium
 
 
 

July 2015

We published the update of the review: Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

 

June 2015

 

We published a new protocol:

-Interventions for smoking cessation in people diagnosed with lung cancer
 

 

 

April 2015

We published a new protocol:

- Maintenance therapy for advanced non-small cell lung cancer

 

 

December 2014

Publication of an updated version of the review:

-Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer
 

 

November 2014

We published two new reviews:

- chemotherapy with cetuximab vs chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

- and our first diagnostic test acuracy review:

PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer

September 2014

Participation of the lung cancer group in the 22nd Cochrane colloquium in Hyderabad (India) from 21 to 26th September. https://colloquium.cochrane.org/

 

 

This month we published two new protocols : 

- Immunotherapy for stage I-III non-small cell lung cancer and

- Third-line systematic treatment for non-small cell lung cancer

 

June 2014

 

Publication of a new protocol: 'Chemotherapy for newly diagnosed inoperable brain metastases from non-small cell lung cancer'

 

 

February 2014

 

Organisation, with the help of Pr. Sculier and the French Cochrane Centre, of a two-day training cession for new authors at the Bordet Institute in Brussels (Belgium). Participation of 12 persons 

 

November 2013

Publication of an updated version of the review : "Chemotherapy versus best supportive care for extensive small cell lung cancer".

 

October 2013

 



 

At the 15th World Conference on Lung Cancer held in Sydney (Australia) on October 2013 the LCG was privileged to run a half day symposium, which involved a number of presentations by some of our editors and authors. There was an excellent turn out with an audience of 80 people from all round the world, a series of great presentations and interesting discussion. The full agenda is below. We hope that this event will stimulate new authors to join us in making the Cochrane Library the premier collection of high quality, up to date, systematic reviews on lung cancer topics.

 

Inaugural Cochrane Workshop :

Chairs : Ramon Rami-Porta (Spain) & Fergus Macbeth (UK)

 

- Introduction to writing a Cochrane review by Fergus Macbeth (UK)

- Writing a protocol by Noelle O'Rourke (UK)

- Defining a review question by Kwun Fong (Australia)

- Searching for studies and selecting studies by Virginie Westeel (France)

- Collection of Data by Nick Pavlakis (Australia)

- Analysing dichotomous data by Chee Khoon Lee (Australia)

- Analysing continuous data by Chee Khoon Lee (Australia)

- Analysing non-standard data and designs by Chee Khoon Lee (Australia)

- Assessing bias in included studies by Lisa Askie (Australia)

- Introduction to meta-analysis by Lisa Askie, (Australia)

- Assessing small study effects and reporting bias by Lisa Askie (Australia)

- Intoduction to RevMan by Ian Yang (Australia)

- Feedback and closing remarks by Ramon Rami-Porta (Spain) & Fergus Macbeth (UK)



 

September 2013

 

The Cochrane Lung Cancer Group officially transferred from Spain to France. The new team would like to thank Xavier Bonfill for his active role in the development of our group and Sera Tort for her support and contribution over the years.